Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck

Inclusion Criteria: * Histological diagnosis of adenoid cystic carcinoma. * Cancer should be staged recurrent or end-stage with/without metastases who have failed all other therapy. * Age ≥ 18 years * ECOG performance status 0-2 (Karnofsky ≥ 50%, see Appendix A). * Patients must have normal organ and marrow function as defined below: * leukocytes ≥ 3,000/mm3 * absolute neutrophil count ≥ 1,500/mm3 * platelets ≥ 100,000/mm3 * total bilirubin \< 1.5 mg/dl OR a stable or a decreasing bilirubin in patients who have undergone placement of an intrabiliary stent * AST(SGOT) ≤ 2.5 X institutional upper limit of normal * ALT(SGPT) ≤ 2.5 X institutional upper limit of normal * creatinine \< 1.5 X institutional upper limit of normal OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. * No known HIV infection. Since NFV is used in HIV patients, we do not want to interfere with the therapy the patient may already be on. * Not pregnant. The effects of NFV on the developing human fetus have been studied in HIV positive women (21). We do not, however, know the risks along with radiation. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician…